Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VALEANT PHARMACEUTICALS INTL INC T.VRX

"Valeant Pharmaceuticals is a global specialty pharmaceutical firm with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The firm also has a branded generics business that operates primarily in Latin America, Eastern Europe, and Asia."


TSX:VRX - Post by User

Post by Stockcoach1on Nov 17, 2015 12:45pm
134 Views
Post# 24297971

House panel wants to speak to former Valeant exec

House panel wants to speak to former Valeant exec
by -ELJAH CUMMINGS, DEMOCRATIC CONGRESSMAN OF MARYLAND | NOV. 17, 2015
Cramer's Mad Dash: Valeant saga continues
 
Jim Cramer explains why he is watching shares of Valeant after its downgrade.
 
The letter noted that although Valeant purchased an option to buy Philidor for $100 million last year, it did not disclose "its connections to this 'phantom captive pharmacy' until last month," after media accounts reported the links.
 
Valeant soon afterward said it would sever ties to Philidor, following a move by three major pharmacy benefits providers to no longer do business with Philidor on the grounds that the company was not in compliance with provider agreements.
 
"Troubling new allegations suggest that a group of Valeant employees helped launch Philidor's business in 2013, and have remained involved in its daily operations," Cummings wrote Pearson. "These allegations suggest that Valeant employees may have been personally involved in questionable billing practices that led Valeant to cut ties with Philidor last month."
The letter cites claims that Valeant employees Patel and Tanner received an email in November 2014 that provided "guidance on ways to re-submit rejected insurance claims to insurance companies in order to obtain higher reimbursement amounts," and also reports that Tanner "has been identified by former Philidor employees as 'a key figure in the pharmacy's operations.'"
 
"These former employees also report being directed to alter physician-written prescriptions so pharmacies would have to dispense Valeant drugs instead of cheaper generic versions to maximize Valeant's profits," Cummings wrote. "Valeant employees reportedly attempted to mask their connections to Valeant by creating fake email identities to conduct their internal Philidor correspondence."
 
In response to Cummings' letter, Valeant spokeswoman Laurie Little said, "We are reviewing the congressman's letter and will respond as appropriate."
 
"As we have said previously, Valeant's board of directors has formed an ad hoc committee to review allegations related to the company's business relationship with Philidor and related matters," Little said.
<< Previous
Bullboard Posts
Next >>